$0.02
(Market cap
$156 Mln
Recently Viewed
Clear AllMarket cap
$156 Mln
Revenue (TTM)
$66 Mln
P/E Ratio
--
P/B Ratio
20.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-2.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-6.9
Debt to Equity
-1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
93,829,188
CFO
€-54.72 Mln
EBITDA
€-23.80 Mln
Net Profit
€-316.57 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Innate Pharma S.A. ADS - ADR
| -17.1 | 23.9 | -18.5 | -26.0 | -21.4 | -18.7 | -- |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Innate Pharma S.A. ADS - ADR
| -4.9 | -34.1 | -24.9 | -18.2 | 11.5 | -36.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Innate Pharma S.A. ADS - ADR
|
1.5 | 155.8 | 2.8 | -47.2 | -86.4 | 734.6 | -- | 20.1 |
| 22.8 | 12,698.2 | 19,628.0 | 978.0 | 9.1 | 6.8 | 11.5 | 0.8 | |
| 28.9 | 1,966.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.1 | 0.5 | |
| 5.3 | 1,177.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 34.0 | 1,638.7 | 29.6 | -24.0 | -- | 31.9 | -- | 65.0 | |
| 5.3 | 535.3 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 4.1 |
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials... for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France. Read more
Co-Founder, Interim CEO & Chairman of Executive Board
Dr. Herve Brailly Ph.D.
Co-Founder, Interim CEO & Chairman of Executive Board
Dr. Herve Brailly Ph.D.
Headquarters
Marseille
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Innate Pharma SA ADS - ADR is $1.45 (NASDAQ) as of 23-Apr-2026 12:27 EDT. Innate Pharma SA ADS - ADR has given a return of -21.43% in the last 3 years.
Since, TTM earnings of Innate Pharma SA ADS - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Innate Pharma SA ADS - ADR are Rs 2.63 and Rs 1.17 as of 23-Apr-2026.
Innate Pharma SA ADS - ADR has a market capitalisation of $ 156 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Innate Pharma SA ADS - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.